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An analysis of the complete Molluscum contagiosum virus (MCV-1) genome sequence revealed a 104-amino-acid open
reading frame (MC148R) that is structurally related to the b (CC) family of chemokines. The predicted MCV chemokine
homolog (MCCH) has a deletion in the NH2-terminal activation domain, suggesting the absence of chemoattractant activity.
The principal objectives of the present study were to determine whether: (i) MCCH is conserved in independent isolates of
MCV-1 and MCV-2; (ii) MCCH mRNA is expressed in vivo; and (iii) the MCCH protein is secreted from mammalian cells. The
nucleotide sequence of the MCCH gene locus was determined for 27 isolates of MCV-1 and 2 of MCV-2 obtained from 29
MCV-infected individuals. In each case, the characteristic CC sequence, the NH2-terminal deletion, and the length of the open
reading frame were conserved, although there were some, mostly conservative, amino acid substitutions. Since MCV cannot
be propagated in cell culture, mRNA was synthesized in vitro by the early transcription apparatus in purified MCV virions.
MCCH RNA was amplified by RT–PCR; the sequence included the complete open reading frame and extended 40 to 50
nucleotides past the first poxviral termination signal (TTTTTNT). Similar RT–PCR results were obtained using total cellular
RNA derived from MCV-infected tissue specimens. Finally, the MCCH open reading frame was expressed in a vaccinia virus
vector and the predicted size polypeptide was secreted into the medium, as determined by Western blotting. Taken together,
our data support the prediction that MCV expresses a secreted chemokine homolog that could antagonize the inflammatory
response in vivo. © 1998 Academic Press
Key Words: Molluscum contagiosum virus; chemokine homolog; DNA nucleotide sequencing; in vitro RNA synthesis;
transcription; RT–PCR.
INTRODUCTION
Molluscum contagiosum virus (MCV) and variola
(smallpox) virus are the only known poxviruses that are
specific for the human host. In contrast to the acute
generalized infection with high mortality caused by var-
iola virus, MCV produces a chronic infection that is
localized to epidermal tissue (Postlethwaite, 1970; Ep-
stein, 1992).
One of the most interesting findings, from the analysis
of the 190,289-bp MCV genome sequence (Senkevich et
al., 1996, 1997), was the identification of a putative gene
product (MC148R, 104 amino acids, genomic nucleotide
position 166,992 to 167,303) with homology to members
of the b or CC family of chemokines. Chemokines are
involved in leukocyte trafficking by specifically mediating
attachment of leukocytes to the vascular endothelium,
leukocyte activation, and diapedesis (Ben-Baruch et al.,
1995; Omz et al., 1996). It was noted, however, that the
predicted MCV chemokine homolog (MCCH) had an ap-
parent deletion in the NH2-terminal region that is re-
quired for chemokine activation of cells (Senkevich et al.,
1996). Consequently, it was suggested that the MCCH
might act as a cellular chemokine antagonist. Such a role
could explain histological data indicating the absence of
mononuclear cells from early MC lesions (Heng et al.,
1989; Viac and Chardonnet, 1990).
To be consistent with a role in preventing inflammation
(i) the MCCH sequence with the noted NH2-terminal
deletion should be generally present in MCV isolates; (ii)
the predicted open reading frame should be transcribed
in vivo; and (iii) the expressed protein should be secreted
from infected cells. To answer the first question, it was
necessary to determine the primary structure of MCCH
genes from independent MCV isolates. The other ques-
tions were difficult to answer because MCV has never
been grown in cell culture and it replicates insufficiently
only in athymic mice containing human skin xenotrans-
plants (Buller et al., 1995). Evidence for transcription of
the MCCH gene was obtained in two ways. The first took
advantage of the fact that permeabilized poxvirus parti-
cles are able to synthesize 59 -capped, polyadenylated,
and translatable mRNA in vitro. This is possible because
the virions carry a DNA-dependent RNA polymerase,
early transcription factor, poly(A) polymerase, and cap-
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ping enzyme (Kates and McAuslan, 1967; Munyon et al.,
1967; Shand et al., 1976). The mRNAs synthesized within
the virus particles are of the early temporal class be-
cause only the early transcription factor is present
(Broyles et al., 1988). The second method was to perform
reverse transcriptase (RT)–PCR on material obtained
from clinical speciments. Finally, we used a vaccinia
virus expression vector to demonstrate that the protein is
secreted from mammalian cells.
RESULTS
Conservation of the MCCH in independent MCV-1
and MCV-2 isolates
The MCCH gene locus of 29 independent MCV iso-
lates was analyzed by DNA nucleotide sequencing.
Based on restriction enzyme analysis of genomic DNA
(Darai et al., 1986), 27 of these isolates were identified
genetically as MCV-1 and the remaining 2 isolates were
of MCV-2 origin. Oligonucleotide primers 1 and 2 (Table
1) were used to amplify 570 bp of the MCCH gene locus.
The primers 1 and 2 correspond to nucleotide positions
130 nucleotides upstream of the initiation codon and 75
nucleotides downstream of the stopcodon, respectively
(Fig. 1). The analysis of the DNA sequences of the am-
plified DNA products revealed that each MCV isolate
contained an intact MCCH coding region 312 nucleotides
in length, encoding a polypeptide of 104 amino acid
residues. The DNA sequences of the MCCH genes de-
rived from 24 of the 29 MCV isolates were found to be
identical to the DNA sequences of the MCCH gene of the
prototype virus isolate (MCV 1/80; GenBank Accession
No. U60315 (Senkevich et al., 1996, 1997)). The results of
this study are shown in Fig. 2. As shown in Fig. 2, minor
DNA sequence variability (deletions and base ex-
changes) occurred upstream of the initiation codon of
the MCCH gene (ORF MC148R of the MCV-1 prototype
virus).
The inferred MCV early promoter consensus se-
quence AAAAGTGAAAAAATA (25 nucleotides upstream
from initiation codon) closely corresponds to the vaccinia
virus early promoter consensus AAAAATGAAAAAATA
(Davison and Moss, 1989). All MCV-1 isolates matched
the consensus (AAAAGTGAACTTCTA), with the nucleo-
tide differences occurring at positions not important for
vaccinia virus early promoter function. Accordingly, it can
be predicted that the MCV chemokine is regulated as an
early poxvirus gene. The promoters of the MCCH genes
of the two MCV-2 isolates had a T3 G substitution that
made the promoter even more vaccinia-like (Fig. 2).
A number of nucleotide exchanges were also ob-
served within the coding region of two isolates of the
MCV-1 variant and two MCV-2 isolates (Fig. 2). The ob-
served conservative and nonconservative amino acid
exchanges are shown in Fig. 3. Although the MCCH is 12
amino acid residues longer than human macrophage
inflammatory protein 1-b (hMIP1b), the deletion of the
active site was maintained in all MCV isolates, suggest-
ing that none encode a protein with chemoattractant
activity. The canonical cysteine residues of b chemo-
kines (Ben-Baruch et al., 1995) were conserved in all
MCV isolates at the amino acid positions 30/31, 59, and
FIG. 1. Diagram showing the genomic localization of the MCCH gene (ORF-MC148R; NP: 166,992–167,303). (A) BamHI physical map of the 190-kbp
MCV-1 genome. (B) Open reading frames located between genome positions 166,724 and 170,391. (C) The MCCH genelocus (570 bp length, NP
166,832–167,402) was amplified by PCR using primers 1 and 2. The ORF is preceded by an AT-rich early poxviral promoter sequence 26 nucleotides
upstream of the ATG and terminated with TAA. An early poxvirus polyadenylation signal TTTTTNT is located 41 nucleotides downstream of the stop
codon.
52 BUGERT ET AL.
FIG. 2. Alignment of the nucleotide sequence of the MCCH gene locus derived from 29 different MCV isolates. The nucleotide sequence of the virus
isolate MCV-1/80 corresponds to the DNA sequence of the MCV-1 prototype (GenBank Accession No. U60315; Senkevich et al., 1996). Promoter,
initiation, termination, and polyadenylation signals as well as nucleotide exchanges are shown underlined and in bold letters. Nucleotide exchanges
in the promoter region are only underlined. Gaps are indicated at the position of nucleotide deletions.
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75 (Fig. 3). In contrast to other known b chemokines, the
MCCH has two additional cysteine residues at positions
94 and 101 which are also conserved in all 29 MCV
isolates analyzed (Fig. 3). Other general features of the
MCCH were preserved in the sequences of all MCV
isolates (Fig. 3) including a N-terminal signal peptide of
24 amino acids. It has to be emphasized that no frame
shifts and/or truncations were observed within the cod-
ing regions of the MCCH genes of any of the MCV
isolates investigated.
MCV in vitro transcription and rapid amplification
of 39-cDNA ends (39-RACE)
Poxviral early mRNA transcripts are synthesized and
extruded from viral cores in an ATP-dependent reaction.
In order to determine whether the MCV chemokine gene
is indeed transcribed as an early gene, MCV virions were
used to synthesize MCV mRNA in vitro by the virion-
associated early transcription complex. The efficiency of
permeabilized MC virions to synthesize mRNA in vitro
was quantitated by [a-32P]UTP labeling. Incorporation of
[a-32P]-labeled UTP during in vitro mRNA synthesis was
plotted against time (Fig. 4). This experiment shows that
under the conditions used, [a-32P]UTP-labeled MCV
mRNA was extruded into the reaction supernatant and
was enriched by a factor of 10 in comparison to core-
associated mRNA. For all further experiments with in
vitro synthesized MCV mRNA the supernatant containing
the soluble MCV mRNA fraction was used. The specific-
ity of the in vitro synthesized [a-32P]UTP-labeled soluble
MCV mRNA was determined by Northern blot (data not
shown).
MCV chemokine transcripts were amplified by RT–
PCR from MCV mRNA synthesized in vitro by permeab-
ilized MCV-1 virions. The MCV-specific cDNA was syn-
thesized from in vitro transcribed MCV mRNA using a
specifically designed primer 5 (Table 1). This oligonucle-
otide primer contains 16 nucleotides of MCV unrelated
M13 sequences followed by 25 thymidine residues that
can specifically bind to poly(A) tails found in eucaryotic
mRNAs. Two additional oligonucleotide primers (primers
3 and 6; Table 1) were designed to bind MCV chemokine-
specific sequences from the previously synthesized MCV
cDNA. The oligonucleotide primer 3 is complementary to
the 59 end of the MCCH gene. The oligonucleotide primer
6 binds to M13-specific sequences (Table 1). As shown
in Fig. 5 (lane 4) a distinct PCR product of about 450 bp
was obtained (Fig. 5). To confirm the identity of the
amplified DNA fragment, DNA nucleotide sequences of
several independent RT–PCR products were determined.
The DNA nucleotide sequences of all RT–PCR products
were identical with exception of their 39 termini and
FIG. 3. Alignment of the amino acid sequences of the MCCH genes derived from 29 different MCV isolates. Exchanged amino acid residues are
underlined and in bold letters. The CC chemokine conserved canonical cysteine residues at amino acid positions 30/31, 59, and 75 are marked by
large and bold letters. The hypothetical receptor binding site (LARRK) is indicated in bold italic letters. The signal peptide sequence (amino acid
residues 1 to 24) is underlined. The asterisks and dots show the positions of identical and well-conserved amino acid residues, respectively.
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found to be full-length MCCH transcripts. The obtained
DNA sequences differed by up to 9 nucleotides in length.
One cDNA sequence that is terminated 100 nucleotides
downstream of the stop codon and 49 nucleotides down-
stream of the transcription termination signal is shown in
Fig. 6 (cDNA-RNA-in-vitro). Between 40 and 50 nucleo-
tides downstream of the transcription termination signal,
all transcripts were terminated consistent with previous
studies with vaccinia virus (Yuen and Moss, 1987). This
experiment indicates, that the MCV chemokine gene is
transcribed as an early gene in vitro.
Transcription of the MCCH gene in human infected
skin tissue
After the successful detection of MCV chemokine tran-
scripts as an early MCV gene product in vitro, it was
necessary to investigate whether the MCV chemokine
transcript is also detectable in vivo. Total RNA was pre-
pared from an MCV-infected skin specimen and ana-
lyzed under the conditions described above. The 450-bp
RT–PCR product (Fig. 5; lane 5) was similar in size and
identical in sequence (Fig. 6; cDNA-RNA-in-vivo) to the
previously observed RT–PCR products obtained from in
vitro transcribed MCV mRNA. The analysis revealed that
the MCV mRNA transcript was terminated 106 and 55
nucleotides downstream of the MCV chemokine stop
codon and the termination signal, respectively. This ex-
periment indicates that the MCV chemokine gene is
transcribed in skin of MCV-infected patients.
TABLE 1
Properties of Oligonucleotide Primers Constructed for Analysis of the MCV Chemokine Homolog Gene Locus
and for Detection of MCV mRNA
Oligonucleotide primers Primer nucleotide position Primer length
EcoRI
Primer 1: 59-GCGCGG-GAATTC-TCTTGAATGTCGCGACGGAGATGGACACAGC-39 166,832–166,862 43
Primer 2: 59-TCGGAAGGGCTGCATGGTGTG-39 167,402–167,382 21
EcoRI NdeI
Primer 3: 59-GCGCGG-GAATTC-CATATGAGGGGCGGAGACGTCTTCGCGAGCGTTGTC-39 166,992–167,024 48
BamHI
Primer 4: 59-GCGCGG-GGATCC-TTACAGAGACTCGCACCCGGACCATATCTGAGGGC-39 167,272–167,306 47
EcoRI
Primer 5: 59-ATCG-GAATTC-CTAAAACGACGGCCAG-TTTTTTTTTTTTTTTTTTTTTTTTT-39 51
EcoRI
Primer 6: 59-ATCG-GAATTC-CTAAAACGACGGCCAGT-39 27
FIG. 4. Kinetics of the MCV mRNA synthesis by permeabilized mol-
luscum contagiosum virions. Transcription reactions were performed
as described under Material and Methods. Incorporation of [a-32P]UTP
into released (h)or core-associated (n) MCV RNA is plotted as a
function of time.
FIG. 5. Detection of MCV-1 chemokine transcript by RT–PCR. Anal-
ysis of PCR products by agarose slab gel electrophoresis. Lanes 1 and
10: 100-bp ladder molecular weight marker. PCR product obtained from
viral DNA using primers 3 and 4 served as positive internal marker
(lane 2). Negative internal control in which viral DNA was tested by
RT–PCR using primers 5 and 6 is shown in lane 3. The PCR products
obtained from cDNA using primers 3 and 6 from in vitro transcribed
viral RNA (lane 4), amplification of MCV-1 chemokine transcripts from
total RNA derived from an MCV-1-infected tissue specimen (lane 5),
and from total mRNA derived from a transfectant cell line (P815-mouse
mastocytoma) harboring the MCV-1 chemokine gene (2) (lane 6). Lanes
7 to 9: PCR assays identical to the RNA preparations of lanes 4 to 6 in
which the RNA was treated with RNase prior to cDNA synthesis.
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The MCCH protein is secreted from mammalian cells
The predicted amino acid sequence of the MCCH
suggested the presence of an NH2-terminal signal pep-
tide and the absence of a C-terminal transmembrane
region. Therefore, we thought that the protein might be
secreted from infected cells. Since MCV cannot be
grown in tissue culture, we constructed a recombinant
vaccinia virus with the MC148L open reading frame. The
cell-free supernatant obtained from BSC-1 cells which
were uninfected, infected with vaccinia virus strain WR,
or infected with the recombinant virus was collected and
analyzed by SDS–polyacrylamide gel electrophoresis
and Western blotting with antiserum to a 34-amino-acid
MC148L-derived peptide. A protein of 10 kDa was de-
tected only in the supernatant from BSC-1 cell cultures
infected with the recombinant virus (Fig. 7). Preimmune
sera of immunized rabbits which served as controls did
not recognize MCCH. This indicates that the MCCH was
synthesized and secreted in the medium as expected
from the predicted protein feature.
DISCUSSION
The detection of interleukin 8 (Bagglioni et al., 1994;
Ben-Baruch et al., 1995) was followed by the discovery of
a family of polypeptides known as cellular chemokines
or intercrines (Miller and Krangel, 1992). This finding
contributed important new knowledge to our understand-
ing of the human inflammatory response. The analysis of
the complete genome of MCV (Senkevich et al., 1996) led
to the identification of the first known viral chemokine
homolog (ORF MC148R) related to the b chemokine
family (Miller and Krangel, 1992; Schall et al., 1990).
Recently, Russo and co-workers reported that the ge-
nome of Kaposi sarcoma-associated herpesvirus (HHV8)
encodes homologs to three cytokines, including two
macrophage inflammatory proteins and interleukin 6
(Russo et al., 1996). The typical arrangement of four
cysteine residues within the MCV chemokine sterically
favors the disulfide bonding pattern and the general
conformation of a chemotactic factor (Ben-Baruch et al.,
1995). However, the absence of 5 of 10 N-terminal amino
acid residues in the receptor activation area may indi-
cate an inability to trigger a biological reaction in the
target cell while the molecule is still able to bind the
receptor. Therefore, an anti-inflammatory activity result-
ing from competition of the viral homolog with cellular
chemokines at the target cell receptor was proposed
(Senkevich et al., 1996). Such a role is supported by a
recent report that MCCH block the chemotactic response
of monocytes to MIP-1a (Krathwohl et al., 1997). This
model assumes that the MCCH gene sequence, includ-
ing the putative inactivating deletion, is present in inde-
pendent MCV isolates; that the gene is expressed in skin
lesions; and the protein is secreted from mammalian
cells. However, due to the fact that MCV cannot be
replicated in cell or tissue culture and there is no animal
system for propagation of MCV, the conventional virolog-
ical techniques cannot be employed for the character-
ization of the MCCH gene product. In the present study,
we first demonstrated that the MCV ORF MC148R is
present in all viral isolates tested, regardless of their
FIG. 6. Alignment of the DNA nucleotide sequence of the cDNA of the 39 end of MCV-1 chemokine transcripts with the corresponding DNA
sequence of the MCV-1 prototype (MCV-1/80). cDNA sequences of MCV chemokine transcripts were obtained by rapid amplification of 39-cDNA ends
(39 RACE) from in vitro transcribed RNA derived from permeabilized MCV-1 virions (cDNA-RNA-in vitro) and from total RNA derived from MCV-1-
infected human skin tissue (cDNA-RNA-in-vivo). Stop codons and polyadenylation signals are shown underlined and in bold letters.
FIG. 7. Expression of the MC148 gene as a secreted protein by
recombinant vaccinia virus. BS-C-1 cells were mock infected (lane 1) or
infected with vJJBcc133-2.5.1. vaccinia virus (lane 2) or WR vaccinia
virus (lane 3) and samples of the media were analyzed by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis. The proteins were
transferred to a nitrocellulose membrane and incubated with a poly-
clonal antiserum to the MC148 gene product. Immune complexes were
detected by chemiluminescence.
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origin. The apparent NH2-terminal deletion was con-
served in all genes and no frameshift changing inser-
tions or deletions were observed, despite the occurrence
of point mutations within the coding sequences. The
single amino acid changes in the MCV-2 chemokine
homolog were mostly conservative, suggesting that they
are not of functional importance. Nevertheless, the
amino acid sequence variation in the two MCV-2 isolates
from geographically distant areas (MCV-2-HD-95/7 from
Germany and MCV-2-UK-66 from Scotland) were nearly
identical.
RT–PCR was used to characterize the MCCH mRNA
synthesized in vitro. The fact that the MCCH gene was
transcribed by purified MCV particles was consistent
with the presence of a consensus early promoter (Davi-
son and Moss, 1989). Furthermore, all analyzed tran-
scripts ended between 40 and 55 nucleotides down-
stream of the TTTTTNT early transcription termination
signal that was first described for vaccinia virus (Yuen
and Moss, 1987). Neither intermediate nor late classes of
mRNA are terminated after that signal. Thus, MCV and
vaccinia virus use the same transcriptional regulatory
mechanisms, as also predicted from the conservation in
MCV of all proteins known to be involved in vaccinia
virus transcription (Senkevich et al., 1997). The RT–PCR
technique also permitted us to demonstrate the pres-
ence of the MCCH mRNA in an infected skin lesion.
Moreover, the length and the sequence of the cDNAs
were the same as those obtained for the in vitro mRNA.
Finally, we used vaccinia virus as a surrogate poxvirus
to demonstrate that the MCCH can be secreted from
mammalian cells. The 10-kDa mass of the polypeptide,
experimentally determined from the mobility of markers,
closely matched the predicted mass of 9.87 kDa. It will
be interesting to determine whether such recombinant
vaccinia viruses can inhibit the inflammatory response in
the skin of experimental animals.
MATERIAL AND METHODS
Virus and recombinant plasmids
A collection of 29 MCV isolates was obtained from
independent MCV-infected individuals and used for the
screening of the MCCH gene locus. The recombinant
plasmid harboring the specific DNA sequences of the
MCV-1 prototype used in this study were described pre-
viously (Darai et al., 1986; Bugert and Darai, 1991). Vac-
cinia virus strain Western Reserve (WR) was grown in
HeLa S3 cells as described elsewhere (Broyles et al.,
1988).
Construction of recombinant vaccinia virus
Recombinant vaccinia virus harboring the MCCH gene
was constructed using the method described by Blasco
and Moss (1995). The MCV ORF 148R was amplified from
the recombinant plasmid pMCV-1-B-C1 by PCR using
primers 3 and 4 (Table 1). The 342-bp amplification prod-
uct was directly cloned into the TA cloning vector pCRII
(Invitrogen). The gene was excised using the restriction
endonuclease EcoRI and subcloned into the vaccinia
donor plasmid vector pRB21 under the control of the
vaccinia virus strong synthetic early/late promoter
(Blasco and Moss, 1995). Orientation of the MCCH gene
in the resulting recombinant plasmid pJB133 was deter-
mined by BamHI restriction and gel electrophoresis.
CV-1 cells were then infected with the F13L deletion
mutant vRB12 and transfected with the donor plasmid as
described previously (Blasco and Moss, 1995). After 48 h
the cells were harvested by scraping, collected by cen-
trifugation, freeze–thawed three times, and sonicated.
Serial dilutions were added to confluent BS-C-1 mono-
layers, overlaid with medium containing 1% low melting
agarose and individual plaques were isolated. The
plaque purification was repeated two more times and the
virus was amplified in BSC-1 cells as described (Blasco
and Moss, 1995). The presence of the MCCH gene in the
purified virus was tested by PCR using primers 3 and 4.
The recombinant vaccinia virus containing the MCCH
gene was subsequently termed vJJBCC133-2.5.1.
Western blot detection of MCCH
Confluent BSC-1 cells (5 3 105) were mock infected or
infected with 5 3 106 PFU of sonicated and trypsin-
treated recombinant or WR virus in 1 ml of EMEM with
2.5% FBS. After 1 h, the volume of the medium was
increased to 3 ml. At 6 h, the medium was removed and
1 ml of EMEM with 0.5% FBS was added to the cells.
After an additional 27 h, the medium was collected and
clarified by centrifugation. A 30-ml sample of infected or
uninfected cells was mixed with an equal volume of
tricine loading buffer, heated to 96°C for 5 min, and then
applied to a Tris–tricine polyacrylamide (16.5%) gel. Pro-
teins contained in the gel were transferred onto a 0.2-mm
nitrocellulose membrane (Schleicher & Schuell, Dassel,
Germany) at 150 mA for 90 min in Tris–glycine buffer. The
membranes were blocked overnight in 3% dried milk–
PBS and incubated with a 1:200 dilution of rabbit poly-
clonal antipeptide sera for 1.5 h. Subsequent steps fol-
lowed manufacturer’s instructions for the commercially
available ECL (Amersham) kit. A 20-s exposure was
used. The polypeptide used to raise rabbit polyclonal
antiserum was derived from the N-terminal sequence of
MCCH (25-LARRKCCLNPTNRPIPNPLLQDLSRVDYQIG-
HDC-59) and coupled to KLH (keyhole limpet hemocya-
nine) prior to immunization of rabbits.
In vitro RNA synthesis by permeabilized virions
MCV virions were isolated from MCV lesion material
by centrifugation through a 36% sucrose cushion. Vac-
cinia virions were purified from infected HeLa cells by
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sucrose gradient centrifugation. The virions were resus-
pended in 1 mM Tris–HCl, pH 8.0, adjusted to the optical
density of 1 OD at 260 nm, and stored at 280°C.
The in vitro transcription assay is based on a protocol
described by Shand et al. (1976) and has been modified
for the production of mRNA suitable for RT–PCR. Virus
suspension (50 ml) (OD260 5 1) was incubated in a
volume of 200 ml with in vitro transcription buffer con-
taining 1.0 M Tris–HCl, pH 8.5, 50 mM MgCl2, 0.25%
2-mercaptoethanol, 0.05% Nonidet P-40, 20 ml of 75 mM
phosphoenolpyruvate, 4.0 mg pyruvate kinase, 1.0 ml
RNasin (40 U/ml, Boehringer, Mannheim, Germany), 4.0
mM ATP, and 2.0 mM CTP, UTP, and GTP at 35°C for 120
min. For synthesis of radioactively labeled MCV mRNA
the reaction was incubated for 180 min and UTP was
substituted by 0.2 mM [a-32P]UTP (sp act 1–3 3 103
Ci/mmol; New England Nuclear, Dreieich, FRG). Four
aliquots (each 20 ml) were taken at different times (0, 60,
120, and 180 min), and soluble and core-associated RNA
were separated by centrifugation, filtrated on nitrocellu-
lose, and washed three times with 10% trichloroacetic
acid, and the incorporated radioactivity was measured in
a Beckman scintillation counter. The remaining superna-
tant was phenol/chloroform extracted and ethanol pre-
cipitated in the presence of 3.0 M sodium acetate, pH
5.3. Unincorporated nucleotides were removed over
Sephadex G50 columns. The [a-32P]UTP-labeled in vitro
transcribed MCV mRNA was hybridized to MCV and
vaccinia viral DNA and recombinant plasmids harboring
MCV viral DNA fragments were immobilized on nitrocel-
lulose membranes. Unlabeled in vitro transcription reac-
tions were treated under the same conditions as de-
scribed above and used for RT–PCR. Twenty units of
RNase inhibitor was added to the RNA sample, and the
reaction was treated with 1.0 ml (40 U/ml) DNase/RNase
free.
RNA extraction from MCV-infected human tissue
MCV-1-infected human skin samples were immedi-
ately frozen at 220°C. Total cellular RNA was extracted
from five individual MCV lesions by the guanidinium/
cesium chloride method (Glisin et al., 1974; Ullrich et al.,
1977) as described by Sambrook et al. (1989). RNA was
screened by RT–PCR as described below.
Polymerase chain reaction and RT–PCR
Oligonucleotide primers used for PCR were synthe-
sized according to the coding sequences of the MCV-1
ORF MC148R and its flanking regions. The properties of
all primers used in this study are summarized in Table 1.
PCR was performed using 0.01 fmol of MCV DNA in 50-ml
volumes containing 50 mM KCl, 10 mM Tris–HCl, pH 8.3,
1–2 mM MgCl2, 1.5% Formalin, 200 mmol of each dNTP,
1.0 mmol of each primer, and 0.5 U of Taq polymerase
(Perkin–Elmer). Twenty-five cycles were run in an auto-
mated temperature cycling reactor (Perkin–Elmer Gene-
amp 2400) which provided 30 s of incubation at 96°C and
4 min at 60°C per cycle. A final incubation step at 72°C
for 7 min was used to extend all unfinished product. The
amplified product was phenol/chloroform extracted and
precipitated in ethanol. The DNA nucleotide sequence
analysis of the MCCH gene locus was performed using
primer 1 (Table 1), located 130 bp upstream of the initi-
ation codon, and primer 2 (Table 1) located 75 bp down-
stream of the stop codon.
For RT–PCR experiments AMV reverse transcriptase
and LA Taq polymerase (TaKaRa- Shuzo Co., Ltd., dis-
tributed by Boehringer Ingelheim, Germany) were used.
For cDNA synthesis an oligo(dT) primer was designed
with an universal M13 primer binding site (primer 5,
Table 1). For amplification of the MCV chemokine-spe-
cific cDNA sequences oligonucleotide primers 3 and 6
(Table 1) were used. Primer 6 contains the universal M13
primer binding sequences incorporated into the oligo(dT)
adapter primer (primer 5, Table 1). The amplification of
the autologous chemokine gene of MCV isolates was
performed using primers 3 and 4 (Table 1). PCR products
were analysed by slab gel electrophoresis.
DNA sequence analysis
The DNA sequence of the PCR products in this study
was determined with an automated 373 ‘‘Extended’’ DNA
sequencer using the standard terminator cycle sequenc-
ing technique (Applied Biosystems GmbH, Perkin–Elmer
Corp., Germany) using oligonucleotide primers 1 to 3
(Table 1).
Computer-assisted sequence analysis
Nucleotide sequences were compiled using the ABI
sequence navigator software, version 1.2. Nucleotide
and amino acid sequences were analyzed using the
PCGENE program, release 6.85 (Intelligenetics Inc.,
Mountain View, CA).
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